THE STERATEGIC ROLE OF FIBROBLAST GROWTH FACTOR-21IN OBESITY

Abstract

Due to obesity many risk factors arise, such as Type 2 Diabetes, Impaired Glucose Tolerance dyslipidemia, hypertension and metabolic homeostasis and disorder. FGF21 is a key regulating endocrine, lipid metabolism, glucose metabolism. Fibroblast growth factor-21 improves glucose tolerance in obese mice, lowers serum free fatty acids (FFA) & results in weight loss. The FGF-21 in obese & diabetes rodent models create confirmatory metabolic variations which consist of dyslipidemia, hyperglycemia, and a decrease in body weight achieved by insulin sensitivity, glucose uptake in peripheral tissues, rise in energy consumption, fat usage, reducing the production of glucagon on the islet of alpha cells. However, FGF-21 rectifies several metabolic complications and has a promising strategic role in therapeutic aim for treatment of obesity, T2DM, dyslipidemia and other related metabolic complications